Category Archives: Clinical

Following the successful single centre trial at Münster Phagenesis has started recruiting patients to their multi-centre PHAST TRAC trial. Update: The recruitment for PHAST TRAC trial has finished. For more information click here .

In a pilot study conducted in Münster PES enhanced remission of dysphagia as assessed with fiberoptic endoscopic evaluation of swallowing (FEES), thereby enabling decannulation in 75% of patients. This trial is published in Intensive Care Medicine Journal read more.

PHAryngeal electrical stimulation for treatment of neurogenic Dysphagia: a European Registry (PHADER). This observational, prospective, post-market follow-up clinical study is designed to enable Phagenesis to demonstrate the real world clinical outcome of Pharyngeal Electrical Stimulation (PES) for the treatment of dysphagia resulting from different neurogenic disorders. If you are a healthcare … Continue reading →

Swallowing food and drink is part of our daily life and something that we do automatically. Sometimes people who suffer from brain injury (such as stroke) or neurodegenerative disease (such as Parkinson’s Disease) may have difficulties with swallowing which compromises their health. One of the complications … Continue reading →

Manchester, UK – 22 May 2013 − Phagenesis, the world’s leading company in the treatment of dysphagia, has expanded its Series B financing to $17m. In 2011, Phagenesis announced a €7m Series B financing, led by Inventages Venture Capital. The … Continue reading →